文献速递神经核医学放射性药物与辐射防护

11C-BU99008 的首次人体 PET 生物分布与辐射剂量学评价

First evaluation of PET-based human biodistribution and radiation dosimetry of 11C-BU99008, a tracer for imaging the imidazoline2 binding site.
PubMed 文献 · EJNMMI Res · 2018-07-30

本研究为 I 期研究,对 4 名健康受试者单次团注 11C-BU99008(296 ± 10.5 MBq)后行全身 PET/CT 采集 120 分钟,计算器官吸收剂量与全身有效剂量。最高活度浓度见于肾脏和脾脏,最高器官吸收剂量为心壁(0.028 ± 0.002 mGy/MBq),关键器官为心壁,总平均有效剂量为 0.0056 ± 0.0004 mSv/MBq,按典型注射 350 MBq 计为 1.96 mSv。

要点

  • 健康受试者 4 名,单次团注 11C-BU99008(296 ± 10.5 MBq)后行 120 分钟全身 PET/CT。
  • 最高活度浓度见于肾脏和脾脏,关键器官为心壁,其吸收剂量为 0.028 ± 0.002 mGy/MBq。
  • 总平均有效剂量为 0.0056 ± 0.0004 mSv/MBq,按 350 MBq 注射计为 1.96 mSv,与其他 11C 示踪剂无明显差异。

核心结论

  • 首次在人体展示 11C-BU99008 的生物分布,总平均有效剂量为 0.0056 ± 0.0004 mSv/MBq,按典型注射 350 MBq 计为 1.96 mSv。
  • 有效剂量与其他 11C 示踪剂相比无明显差异。

研究设计与样本

  • I 期研究,纳入 4 名健康受试者,单次团注 11C-BU99008(296 ± 10.5 MBq)后行全身 PET/CT 采集 120 分钟,范围自颅顶至大腿中部。
  • 围绕可视识别源器官勾画感兴趣区,生成时间-活度曲线并确定驻留时间,采用 OLINDA/EXM 1.1 计算各受试者各器官吸收剂量与全身有效剂量。

主要发现

  • 最高活度浓度见于肾脏和脾脏。
  • 最长驻留时间见于肌肉(0.100 ± 0.023 h),其次为肝脏(0.067 ± 0.015 h)和肺(0.052 ± 0.010 h)。
  • 最高平均器官吸收剂量为心壁(0.028 ± 0.002 mGy/MBq),其次为肾脏(0.026 ± 0.005 mGy/MBq),关键器官为心壁。
  • 总平均有效剂量为 0.0056 ± 0.0004 mSv/MBq,按典型注射 350 MBq 计为 1.96 mSv。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: We measured whole body distribution of 11C-BU99008, a new PET biomarker for non-invasive identification of the imidazoline2 binding site. The purpose of this phase I study was to evaluate the biodistribution and radiation dosimetry of 11C-BU99008 in healthy human subjects. METHODS: A single bolus injection of 11C-BU99008 (296 ± 10.5 MBq) was administered to four healthy subjects who underwent whole-body PET/CT over 120 min from the cranial vertex to the mid-thigh. Volumes of interest were drawn around visually identifiable source organs to generate time-activity curves (TAC). Residence times were determined from time-activity curves. Absorbed doses to individual organs and the whole body effective dose were calculated using OLINDA/EXM 1.1 for each subject. RESULTS: The highest measured activity concentration was in the kidney and spleen. The longest residence time was in the muscle at 0.100 ± 0.023 h, followed by the liver at 0.067 ± 0.015 h and lungs at 0.052 ± 0.010 h. The highest mean organ absorbed dose was within the heart wall (0.028 ± 0.002 mGy/MBq), followed by the kidneys (0.026 ± 0.005 mGy/MBq). The critical organ was the heart wall. The total mean effective dose averaged over subjects was estimated to be 0.0056 ± 0.0004 mSv/MBq for an injection of 11C-BU99008. CONCLUSIONS: The biodistribution of 11C-BU99008 has been shown here for the first time in humans. Our dosimetry data showed the total mean effective dose over all subjects was 0.0056 ± 0.0004 mSv/MBq, which would result in a total effective dose of 1.96 mSv for a typical injection of 350 MBq of 11C-BU99008. The effective dose is not appreciably different from those obtained with other 11C tracers.

来源:EJNMMI Res,查看原文。版权归原作者所有。

引用

  1. Venkataraman AV, Keat N, Myers JF, et al. First evaluation of PET-based human biodistribution and radiation dosimetry of 11C-BU99008, a tracer for imaging the imidazoline2 binding site. EJNMMI Res. 2018. PMID: 30062395. doi:10.1186/s13550-018-0429-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。